
Ovarian Cancer
Latest News
Video Series

Latest Videos
Shorts

CME Content
More News

Clinical trial data show ovarian cancer survival gaps narrow with diverse enrollment, but disparities persist after progression, spotlighting access, toxicity, and care barriers.

Phase 2 data show elenagen plus gemcitabine extends survival in platinum-resistant ovarian cancer with high CA-125, without added toxicity.

FDA approves pembrolizumab with chemotherapy for platinum-resistant ovarian cancer, showing significant survival benefits in clinical trials.

A recent study reveals significant racial disparities in ovarian cancer trial outcomes, highlighting the urgent need for improved diversity in clinical research.

Gemogenovatucel-T shows remarkable survival benefits in high-risk ovarian cancer patients, highlighting its potential as a new standard of care.

BioInvent's BI-1808 combined with pembrolizumab shows promising antitumor activity in recurrent ovarian cancer, offering hope for better treatment options.

The ROSELLA trial reveals relacorilant plus nab-paclitaxel significantly improves survival in platinum-resistant ovarian cancer without increasing safety risks.

New cancer vaccine MVP-S shows promising results in recurrent ovarian cancer, enhancing immune response and improving treatment outcomes with pembrolizumab.

Sofetabart mipitecan receives FDA breakthrough therapy designation, showing promising efficacy in treating platinum-resistant ovarian cancer.

The SCORES trial reveals suvemcitug significantly enhances survival and disease control in patients with platinum-resistant recurrent ovarian cancer.

A systematic review reveals PARP inhibitors improve progression-free survival in advanced ovarian cancer but lack overall survival benefits, highlighting treatment variability.

ETX-19477 receives FDA fast track designation, promising accelerated development for treating BRCA-mutated, platinum-resistant ovarian cancer patients.

A novel antibody combination shows promising results in treating recurrent ovarian cancer, offering hope for better immunotherapy options.

A phase 2 trial shows ribociclib and letrozole effectively treat recurrent low-grade serous carcinoma, achieving significant response rates and durable control.

JSKN003, a novel HER2-targeting ADC, shows promising efficacy in treating platinum-resistant ovarian cancer, earning FDA breakthrough therapy designation.

A recent trial evaluates the impact of dostarlimab on ovarian cancer treatment, revealing modest benefits and no significant safety concerns with niraparib.

The FDA fast-tracks JSKN003, a promising treatment for platinum-resistant ovarian cancer, enhancing development and approval processes for this critical therapy.

Recent findings from the MIRASOL trial reveal significant advancements in treatment options for platinum-resistant ovarian cancer, emphasizing effective therapy sequencing.

New findings reveal that adding sapanisertib to weekly paclitaxel significantly improves progression-free survival in advanced ovarian cancer patients.

Raludotatug deruxtecan (R-DXd) demonstrates significant antitumor activity and manageable safety in platinum-resistant ovarian cancer, paving the way for further studies.

TUB-040 shows over 50% response rates in platinum-resistant ovarian cancer, highlighting its potential as a promising treatment option.

New findings reveal pembrolizumab combined with paclitaxel enhances survival rates in patients with platinum-resistant recurrent ovarian cancer.

During a live event, Martin A. Martino, MD, analyzed overall survival outcomes from the PAOLA-1, SOLO-1, and PRIMA trials.

New clinical data reveals stenoparib significantly extends survival in advanced platinum-resistant ovarian cancer, offering hope for patients with limited options.

IMNN-001 shows promising results in enhancing the tumor microenvironment and improving survival rates in advanced ovarian cancer treatment.





































